Ranjita Shegokar Ph.D.

[smartslider3 slider="4"]

Ranjita Shegokar Ph.D, EMBA

Dr. Ranjita Shegokar holds a Ph.D. in Pharmaceutical Technology from SNDT University, India, and has completed postdoctoral research at the Free University of Berlin, Germany, specializing in Pharmaceutics, Biopharmaceutics, and NutriCosmetics. She has extensive experience in R&D leadership roles at various multinational German pharmaceutical companies. Currently, she serves as the Chief Pharma Innovation Officer (CPO) at DiHeSys GmbHGermany. She has authored numerous research articles and book chapters and has presented her work at various national and international conferences. She has filed multiple patent applications in the areas of drug delivery and targeting and has edited several influential books on pharmaceutical nanotechnology and drug delivery systems. Dr. Ranjita’s research excellence has been recognized with prestigious awards, including the German Innovation Award in 2022 and the German Medical Award in 2023. Her research interests include polymeric nanoparticles, nanocrystals, lipid nanoparticles (SLNs/NLCs), nanoemulsions, cancer drug targeting, oral solid dosage forms (OSDFs), and the role of excipients in delivery systems. Dr. Ranjita’s professional focus encompasses R&D, intellectual property, trademark, innovation strategies, 2D/3D printed personalized medicines, preclinical models, and their translation to medical/clinical affairs.

Master's – Pharm Tech Pediatric Suppositories
& Lipospheres
Post-Doc. – Pharm Nanotech Dermal and mucosal
drug targeting : Nanoparticles
DFE Pharma GmbH & Co. KG Oral Solid Dosage Forms (OSDFs) Capnomed GmbH Drug targeting/ drug device combinations CapnoPharm GmbH GMP/GCP- Clinical/medical
Affairs in oncology
   PhD – Pharm Nanotech Organ Drug
targeting in HIV
PharmaSol GmbH Dermal/mucosal Nanocrystals,
SLNs-NLCs etc.
Symrise AG Immediate & controlled active
release
EMBA Business Strategy and Growth DiHeSys GmbH 2D & 3D printing - Personlized Medicine

Charged curcumin nanoparticles for aerosolization

Positively charged CUR-PLGA-NPs increased depth of tissue penetration by 81.5% and tissue concentration...

Polymer: Lipid Hybrid Nanostructures in Cancer Drug Delivery:

Liposomes, polymeric, lipid and inorganic nanoparticles have dominated and proved their clinical effectiveness...

Cancer research and therapy: Where are we today?

Advancement in cancer research and therapies is fastened by possibilities of record-breaking technologies...

Bone scaffolds: What’s new in nanoparticle drug delivery

Nanotechnology is being widely studied in bone repair or regeneration treatments in the...

Nanotoxicity: Must Consider Aspect of Nanoparticle Development

Early years are proof of nanoparticle developments and understanding basic mechanisms. With no...

Large-scale manufacturing of nanoparticles—An industrial outlook

Nanosuspensions and lipid nanoparticles are very promising drug delivery systems for overcoming drug-related...